INSL3 Expression in Leydig Cells is a Biomarker for Immunocastration in Boars: Transcriptional Evidence
Andrology · 2026
DOI: 10.1111/andr.70136 ↗At a glance
Journal article in Andrology, 2026. Written by Nina Batorek Lukač and 6 co-authors. Institution: Agricultural Institute of Slovenia, Ljubljana, Slovenia. Major MEDLINE topics: Leydig Cells, Insulin, Proteins. Cited 3 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY 4.0). Funded by: ERA NET SusAn SuSi, Slovenian Research and Innovation Agency.
Abstract (original language)
Background
Study aimed to obtain insights into physiological responses to immunocastration in pubertal boars by evaluating effects of alternative vaccination protocols and identifying a reliable immunocastration biomarker.
Objectives
It was hypothesized that the timing of gonadotropin‐releasing hormone (GnRH) suppression by immunocastration differentially affects reproductive function, as reflected by testicular histology and expression of selected genes related to testicular function, steroid metabolism, and Leydig cell differentiation and function. Materials and Methods Effects of three vaccination protocols on antibody titers, testicular histomorphology, and mRNA expression in immunocastrates slaughtered 4, 8, or 12 weeks (IC‐4, IC‐8, and IC‐12, respectively; n = 6 per group) after booster were compared with entire males (EMs; n = 6). Principal component analysis and hierarchical clustering were used to evaluate individual responses and to identify an immunocastration biomarker(s). The selected biomarker was also validated on samples from previous studies.
Results
All immunocastrated boars reacted immunologically to vaccination (increased GnRH antibody titer; p < 0.004). There was an increased nucleus‐to‐cytoplasm ratio in Leydig cells ( p < 0.033) and decreased testosterone concentration ( p < 0.041) in IC‐4 compared with EM, whereas values in IC‐8 and IC‐12 were intermediate. Hierarchical clustering differentiated immunocastrates with low testosterone (IC‐LT; median 0.56 ng/mL) and high testosterone (IC‐HT; median 7.04 ng/mL). In IC‐LT, expression levels of FSHR and ESR2 were higher than in IC‐HT, and those of LHCGH, STAR and INSL3 were lower compared with IC‐HT and EM, whereas expression of ESR1 and HSD17β7 was lower in IC‐LT and IC‐HT compared with EM (fold change > 1.5 and p < 0.05).
Conclusion
There were variable responses to immunocastration in pubertal boars subjected to three vaccination protocols. Suppression of testicular function was most pronounced in boars slaughtered 4 weeks after the booster, whereas progressive recovery occurred in some boars 8 and 12 weeks after the booster. Irrespective of vaccination protocol, INSL3 mRNA expression was a reliable immunocastration biomarker.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Agricultural Institute of Slovenia, Ljubljana, Slovenia.
- Veterinary Faculty, Institute of Preclinical Sciences, University of Ljubljana, Ljubljana, Slovenia.
- University of Hohenheim, Stuttgart, Germany.
ORCID profiles: Nina Batorek Lukač, Martin Škrlep, Klavdija Poklukar
Funding
- ERA NET SusAn SuSi
- Slovenian Research and Innovation Agency
Cite
APA
Lukač, N. B., Škrlep, M., Poklukar, K., Ferjan, P., Stefanski, V., Fazarinc, G., & Vrecl, M. (2026). INSL3 Expression in Leydig Cells is a Biomarker for Immunocastration in Boars: Transcriptional Evidence. Andrology. https://doi.org/10.1111/andr.70136
Vancouver
Lukač NB, Škrlep M, Poklukar K, Ferjan P, Stefanski V, Fazarinc G, et al. INSL3 Expression in Leydig Cells is a Biomarker for Immunocastration in Boars: Transcriptional Evidence. Andrology. 2026. doi:10.1111/andr.70136
BibTeX
@article{Luka2026,
author = {Lukač, Nina Batorek and Škrlep, Martin and Poklukar, Klavdija and Ferjan, Petra and Stefanski, Volker and Fazarinc, Gregor and Vrecl, Milka},
title = {INSL3 Expression in Leydig Cells is a Biomarker for Immunocastration in Boars: Transcriptional Evidence},
journal = {Andrology},
year = {2026},
doi = {10.1111/andr.70136}
}
EUVIMED